Non-Covalent Molecular Recognition for Drug Targeting in the Body

体内药物靶向的非共价分子识别

• 批准号: 10645209
• 负责人: Matthew Webber
• 金额: $ 38.34万
• 依托单位: UNIVERSITY OF NOTRE DAME
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10645209
• 关键词: Affinity; Antibodies; Attenuated; Binding; Biological; Cells; Chemistry; Devices; Disease; Dose; Drug Delivery Systems; Drug Kinetics; Drug Targeting; Drug or chemical Tissue Distribution; Drug usage; Ensure; Future; Home; Homing; In Situ; In Vitro; Kinetics; Ligation; Methodology; Pharmaceutical Preparations; Physiological; Prodrugs; Property; Proteins; Research; Route; Site; Technology; Therapeutic; Therapeutic Agents; Time; Tissues; Toxicant exposure; Variant; design; implantable device; interest; metabolic engineering; molecular recognition; molecular scale; programs; remote intervention; side effect; small molecule therapeutics; systemic toxicity

PROJECT SUMMARY: Even with an ever-expanding arsenal of active drug molecules validated in vitro, ensuring these reach their desired target in the body, while at the same time limiting toxic exposure in healthy tissue, remains a challenge. Routes for targeting drugs using antibodies or targeted carriers still result in less than 1% of drug arriving at the site of need. Molecular-scale targeting may have inherent advantages relative to these approaches due to more extensive tissue distribution and more rapid clearance of unbound attenuated therapeutic agents, leading to more drug arriving at the site of need or clearing prior to onset of systemic toxicity. Routes using `click' chemistry and related covalent ligations have been explored for homing drugs to pre-targeted sites. Here, we describe our progress and plans in developing a versatile and modular molecular-scale approach that uses synthetic non- covalent affinity to home drugs to desired sites in the body. Relative to covalent molecular-scale approaches, the chemistry we use has faster kinetics of association and also enables future reuse of the targeted site. Through prodrug methodology, we have shown that drugs of interest can be modified with affinity motifs through labile linkers, to be recognized at desired tissue sites by the presence of a corresponding binding partner. Serial re- dosing of these sites, or the possibility to temporally change the drug delivered, adds further benefit to our modular non-covalent approach. With this proposal, we seek to further define this research program and more fully capture the benefits of non-covalent recognition relative to `click'-based alternatives. Specifically, we will elucidate the importance of prodrug design and pharmacokinetic properties. So as to enable serial re-targeting of a drug site – a distinct benefit of non-covalent recognition – we will explore new chemistry for in situ immolation to lower-binding variants. We will also explore this approach in overcoming common physiologic barriers to the administration of protein and small molecule therapeutics, using the systemic administration of innocuous agents to trigger the release of therapeutic compounds bearing affinity tags from locally applied depots. Finally, to expand the therapeutic scenarios wherein this targeting route may be useful, we will explore this affinity axis for integration with metabolically engineered cells. In summary, we are optimistic that the new targeting technology we are developing will unlock the vast therapeutic potential of active agents which are presently limited by systemic toxicity or poor target localization. A platform such as that we are pursuing would have broad application in therapeutic delivery for the treatment of a variety of diseases or for remote intervention in implanted biomedical device practice.

项目总结: